Satoshi Ueshima

Satoshi Ueshima

Auto-generated profile, based on publicly available information

Satoshi Ueshima

College of Pharmaceutical Sciences, Ritsumeikan University, Noji-higashi, Kusatsu-shi, Shiga, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
PDF file
SUSatoshi Ueshima
Satoshi Ueshima
DHDaiki Hira
Daiki Hira
Ryo FujiiRyo Fujii
Ryo Fujii
YKYuuma Kimura
Yuuma Kimura
CTChiho Tomitsuka
Chiho Tomitsuka
TKToshiya Katsura
Toshiya Katsura
During anticoagulant therapy, major bleeding is one of the most severe adverse effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concentrations of apixaban, a direct inhibitor of coagulation factor X. A total of 70 plasma concentrations of apixaban from 44 Japanese patients with atrial fibrillation were analyzed. In these analyses, the plasma trough concentration/dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) polymorphisms. Influences of various clinical laboratory parameters (age, serum creatinine, estimated glomerular filtration rate, aspartate amino transferase, and alanine amino transferase) on the plasma trough C/D ratio of apixaban were included in analyses. Although no ABCB1 polymorphisms affected the plasma trough C/D ratio of apixaban, the plasma trough C/D ratio of apixaban was significantly higher in patients with the ABCG2 421A/A genotype than in patients with the ABCG2 421C/C genotype (P<0.01). The plasma trough C/D ratio of apixaban in patients with CYP3A5*1/*3 or *3/*3 genotypes was also significantly higher than that in patients with the CYP3A5*1/*1 genotype (P<0.05). Furthermore, the plasma trough C/D ratio of apixaban decreased with increased estimated glomerular filtration rate. These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concentrations of apixaban.

1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MKMikio Kakumoto
Mikio Kakumoto
KSKosuke Shimokawa
Kosuke Shimokawa
SUSatoshi Ueshima
Satoshi Ueshima
DHDaiki Hira
Daiki Hira
TOTomonobu Okano
Tomonobu Okano

10 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SUSatoshi Ueshima
Satoshi Ueshima
SNSerina Nagahara
Serina Nagahara
KNKenta Nakaya
Kenta Nakaya
MKMayu Kawamura
Mayu Kawamura
DHDaiki Hira
Daiki Hira
MKMikio Kakumoto
Mikio Kakumoto
The pharmacokinetic and pharmacodynamic characteristics of remimazolam (RMZ), a novel ultrashort-acting anesthetic, administration alone in clinical practice remain poorly understood. Therefore, we aimed to evaluate the relationship between patient characteristics and the pharmacokinetics and pharmacodynamics of RMZ in older Japanese adults who underwent general anesthesia at the early stage of infusion. Plasma samples were collected from 20 patients (median age: 71.7 years; range: 42.2–88.6 years) who were intravenously administered RMZ without other anesthetics such as remifentanil or fentanyl. The pharmacokinetic profiles of RMZ and its metabolite (CNS7054) were described using three- and two-compartment models with a transit compartment, respectively. The bispectral index was selected as a clinical measure of sedation. The pharmacokinetic-pharmacodynamic profile of RMZ was described using a maximum inhibitory model with an effect compartment. The population pharmacokinetic and pharmacodynamic parameters of RMZ were obtained using the nonlinear mixed-effects modeling program. RMZ clearance (CL) was increased nonlinearly with increasing body weight (BW), and the population mean CL for a typical patient (BW, 60.4 kg) was 1.38 L/min. No patient characteristics affected CNS7054 pharmacokinetics. The population mean of the half-maximal inhibitory RMZ concentration decreased nonlinearly with increasing age or BW. However, these characteristics did not meet the criteria for pharmacokinetic and pharmacodynamic covariates. Our results suggest that BW is an intrinsic factor affecting RMZ pharmacokinetics in Japanese patients under general anesthesia in the early stages of infusion; however, no patient characteristics affected RMZ pharmacodynamics.

24 October 2025 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
CFChieri Fujino
Chieri Fujino
SUSatoshi Ueshima
Satoshi Ueshima
FTFukami Tatsuki
Fukami Tatsuki
MNMiki Nakajima
Miki Nakajima
TKToshiya Katsura
Toshiya Katsura
Changes in the expression of drug-metabolizing enzymes and transporters can alter the pharmacokinetics of drugs, potentially affecting their efficacy and safety. In this study, we investigated the effects of decreased multidrug resistance-associated protein (MRP) 2 expression on the gene expression of other drug-metabolizing enzymes and transporters. Variations in the mRNA expression of drug-metabolizing enzymes and transporters were observed in MRP2-knockdown human hepatocellular carcinoma HepG2 cells and the liver of MRP2-deficient Eisai hyperbilirubinemic rats (EHBR). Both models showed decreased mRNA and protein expression of sulfotransferase (SULT) 1E1, a phase II drug-metabolizing enzyme, suggesting a relationship between the transcriptional regulation of MRP2 and SULT1E1. The plasma levels of bilirubin, bile acids, and cholesterol were higher in EHBR than in control Sprague-Dawley rats. Treatment with chenodeoxycholic acid (CDCA), a primary bile acid, reduced SULT1E1 mRNA expression in HepG2 cells and suppressed human SULT1E1 promoter activity in a luciferase reporter assay using HepG2 cells. CDCA is a known agonist of the farnesoid X receptor (FXR), and transcriptome analysis of the EHBR liver also suggested FXR activation, as inferred from changes in its target gene expression. These findings suggest that decreased MRP2 expression causes coordinated changes in the SULT1E1 gene expression via FXR activation by endogenous substances. These indirect changes in the expression of drug-metabolizing enzymes or transporters should be considered during drug development and in clinical practice. SIGNIFICANCE STATEMENT: This study investigated compensatory or coordinated changes in gene expression of drug-metabolizing enzymes and transporters in multidrug resistance-associated protein (MRP) 2-knockdown HepG2 cells and in the liver of MRP2-deficient rats. Decreased expression of MRP2 affects the gene expression of drug-metabolizing enzymes and transporters, including a decrease in SULT1E1, likely through nuclear receptor activation by endogenous molecules.